By Cecilia Butini 

AstraZeneca PLC said Wednesday that the U.S. District Court for the Northern District of West Virginia has decided in its favor in litigation regarding patents protecting its asthma medication Symbicort.

Litigation was against Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery LP and was initiated with claims of infringement of various U.S. patents covering Symbicort, the British pharmaceutical giant said.

A third company, 3M Co., was initially part of the lawsuit but later dismissed from the case, AstraZeneca said.


Write to Cecilia Butini at


(END) Dow Jones Newswires

March 03, 2021 02:34 ET (07:34 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.